Synthesis and antitumor evaluation of some new derivatives and fused heterocyclic compounds derived from thieno[2,3‐<i>b</i>]pyridine: Part 2

Abstract

Abstract As a continuation of our research on developing anticancer agents and based on the proven proprieties of thieno[2,3‐ b ]pyridines as anticancer, we have designed to synthesize novel thieno[2,3‐ b ]pyridine derivatives that incorporate different biologically active heterocycles through various chemical reactions. All of the newly obtained compounds, compared with the standard anticancer drug (doxorubicin), were screened in vitro for their antitumor activity against hepatocellular carcinoma (HepG‐2) and human breast cancer (MCF‐7) cell lines. The results revealed that compounds 3 , 7 , 12 , and 19 were found to be the most potent against both HepG‐2 and MCF‐7 cell lines exhibiting IC 50 values ranging from 3.67 to 11.50 and 5.13 to 11.80 μg/mL, respectively, among which compound 7 has a more potent activity than the reference drug doxorubicin against HepG‐2 cell line, showing IC 50 value of 3.67 μg/mL (doxorubicin 4.65 μg/mL).